Inventor
Jeffrey David ST. DENIS
Inventor
GB
Overview
Patents· 6 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07DHeterocyclic compounds25%
C07BGeneral methods of organic chemistry21%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
PatentTitleYear
12,077,526Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them202412,071,429Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity202412,037,345Heterobicyclic compounds for inhibiting the activity of SHP2202411,603,367Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them202311,466,016Pharmaceutical compounds202211,261,171Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to ASTEX THERAPEUTICS LTD (4)· patent assignee history
2022–2024Patents assigned to CANCER RESEARCH TECH LTD (4)· patent assignee history
2022–2024Patents assigned to OTSUKA PHARMA CO LTD (2)· patent assignee history
2022–2024Patents assigned to TAIHO PHARMACEUTICAL CO LTD (2)· patent assignee history
2022–2024Based in GB· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ASTEX THERAPEUTICS LTD | 4 | 2022–2024 |
| CANCER RESEARCH TECH LTD | 4 | 2022–2024 |
| OTSUKA PHARMA CO LTD | 2 | 2022–2024 |
| TAIHO PHARMACEUTICAL CO LTD | 2 | 2022–2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| GB | 6 | 2022–2024 |